Concepedia

Ryo Toyozawa

RT

Statistics

Publications

45

Citations

2.3K

H-Index

21

Active since

2013

Affiliations

National Hospital Organization Kyushu Cancer Center(Current)

Kyushu University

Kindai University

National Cancer Center Hospital East

Kurume University

Ryo Toyozawa is an author at National Hospital Organization Kyushu Cancer Center specializing in oncology, medicine, and molecular oncology.

Publications per year

2013–2025

45

Publications

45

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori et al. · Journal of Thoracic Oncology · 2022 · 158 citations

Medicine, Oncology, Pharmacotherapy +8

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

Alexander Drilon, Geoffrey R. Oxnard, Lori J. Wirth et al. · Journal of Thoracic Oncology · 2019 · 81 citations · Full text

Medicine, Oncology, Cancer Genetics +10

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Makoto Nishio, Tatsuya Yoshida, Toru Kumagai et al. · Journal of Thoracic Oncology · 2020 · 68 citations

Medicine, Oncology, Pharmacotherapy +12

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab

Taichi Matsubara, Shinkichi Takamori, Naoki Haratake et al. · Journal of Thoracic Disease · 2020 · 66 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 45